
Opinion|Videos|September 11, 2024
Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?
Advertisement
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What Does the Future Hold for Nuclear Medicine?
2
From Adoption to Governance in Radiology: Navigating the Next Wave of Imaging AI
3
Top Five Radiology Video Interviews in June 2026
4
Mammography News: FDA Clears New Functionalities for DeepHealth’s AI-Powered Breast Suite
5











